Androgen plays an important role in female sexual function, and its insufficiency causes a clinically significant sexual dysfunction. This study examines the association between sex hormones and the clinical effect of testosterone replacement therapy in female sexual dysfunction.

This study examined 75 female patients who visited our hospital from March 2002 to June 2008 to treat sexual dysfunction. For the rest of the patients, we performed primary treatment and physiotherapy in accordance with the main cause of their sexual dysfunction. We also performed combination treatment of androgen replacement therapy for the patients who did not make medical progress after two months of primary treatment and for the patients whose free testosterone level is in the bottom group out of three normal range groups.

The mean age of target patients was 39.6±8.7 years (range, 35~66 years) old. 10 patients out of 75 patients were postmenopausal women, and estrogen replacement therapy had been performed without androgen replacement therapy. We performed a combination treatment of androgen replacement therapy for the patients with sexual desire disorder, and 60% of them answered that they had an increased sexual response after they were given combination treatment of androgen replacement therapy.

The results support the concepts that sex hormones significantly affect sexual response in women with sexual dysfunction. Clinically, it is effective and safe to perform a combination treatment of androgen replacement therapy in treating sexual dysfunction if medication is administered properly and carefully.

Chronic kidney disease(CKD) and Sexual dysfunction are important public health problems in older man as a part of life. We investigated the relationship between two groups.

We examined sixty-five CKD patients on glomerular filtration rate (GFR), serum creatinine (sCr), Prevalence period and causative disease. Sexual function was evaluated by International Index of Erectile Function(IIEF-5), libido(2 items), ejaculation(4 items), frequency of sex in a month and serum testosterone. A control group composed of eighteen male adults who had visited to the general medical testing center in the hospital. They didn't have any combined disease and they were similar age range to the group of the CKD. We analyzed correlations between components of the CKD and sexual function.

The study revealed that all sexual components of the CKD group(mean age 51.8±2.6) were significantly worse than the control group; 12.3±3.9 of IIEF-5, 5.4±1.8 of libido and 10.1±2.2 of ejaculation, 1.4±0.7times of sex in a month in the CKD group and 18.3±3.5 of IIEF-5, 7.2±2.1 of libido and 15.3±2.9 of ejaculation, 2.9±1.1 times of sex in a month in the control group. The patients whose prevalence period of CKD was over than 3 years or whose sCr was over than 2.0ng/ml, had all sexual components worse significantly. Comparing by the causative disease of the CKD, there was no any significant difference. Analyzing by correlation, erectile function is related with serum glucose, sCr, Prevalence periods and libido is related with prevalence periods, and ejaculation is related with diabetes.

The patients with CKD may have a sexual dysfunction that make erection, libido and ejaculation and the number of their sex seemed to decrease. Therefore we need to have more attention to their sexual function as an important part of life.

It is important to improve treatment efficacy in the management of urolithiasis in respect of time saving cost effectiveness. An experimental study reported that optimal fluid act as an interface between stone and urothelium improves fragmentation. We investigated the effect of diuretic usage in the SWL treatment of urolithiasis.

Sixty renal stone patients were selected for the prospective randomized double blind study. Patient in group A were given a placebo injection and patient in group B were given 20mg IV furosemide at the time of SWL treatment. Both groups received standard SWL monotherapy using Modulith SLX2000 lithoclast(Storz®, Germany). The energy setting, number of shock waves per session were identical in both groups. Treatment results were compared three weeks later after the first SWL treatment.

Mean age of the patients was 44.5±11.3 years old in group A, and 43.1±11.5 years old in group B. Mean size of the calculus before treatment were 9.2±4.8, and 8.9±5.1mm, which did not shown any statistical difference(p>0.05). Three weeks after the treatment, stone fragmentation and stone free rate was significantly higher in group B(p<0.05).

This study suggest that administration of furosemide intravenously during SWL improve stone fragmentation and stone free rate.